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Alterations in non-enzymatic biochemistry in uremia: Origin The long-term survival and quality of life of uremic
and significance of “carbonyl stress” in long-term uremic com- patients given renal replacement therapy are now deter-
plications. Advanced glycation end products (AGEs), formed mined largely by complications that develop early in theduring Maillard or browning reactions by nonenzymatic glyca-
course of renal failure, such as cardiovascular disease,tion and oxidation (glycoxidation) of proteins, have been impli-
cated in the pathogenesis of several diseases, including diabetes bone disorders, or even dialysis-related amyloidosis. Fac-
and uremia. AGEs, such as pentosidine and carboxymethylly- tors responsible for these disorders have been intensively
sine, are markedly elevated in both plasma proteins and skin investigated. Some are now prevented, at least in part, bycollagen of uremic patients, irrespective of the presence of
various approaches, including antihypertensive therapy,diabetes. The increased chemical modification of proteins is
lipid-lowering drugs, calcium regulating agents, etc. Thenot limited to AGEs, because increased levels of advanced
lipoxidation end products (ALEs), such as malondialdehyde- recognition that uremic complications are related to the
lysine, are also detected in plasma proteins in uremia. The accumulation of toxic metabolites in blood and tissues
accumulation of AGEs and ALEs in uremic plasma proteins
has led to efforts to identify the causal agents, to inhibitis not correlated with increased blood glucose or triglycerides,
their formation, and to enhance their detoxification ornor is it determined by a decreased removal of chemically
modified proteins by glomerular filtration. It more likely results accelerate their removal by dialysis procedures.
from increased plasma concentrations of small, reactive car- The discovery that proteins are progressively and irre-
bonyl precursors of AGEs and ALEs, such as glyoxal, meth-
versibly modified with advanced glycation end productsylglyoxal, 3-deoxyglucosone, dehydroascorbate, and malondi-
(AGEs), by a nonenzymatic Maillard or browning reac-aldehyde. Thus, uremia may be described as a state of carbonyl
overload or “carbonyl stress” resulting from either increased tion during the normal process of aging, has opened new
oxidation of carbohydrates and lipids (oxidative stress) or inad- avenues for research on uremic toxicity. This process is
equate detoxification or inactivation of reactive carbonyl com- markedly accelerated in diabetes and also contributes topounds derived from both carbohydrates and lipids by oxida-
the development of diabetic complications.tive and nonoxidative chemistry. Carbonyl stress in uremia
may contribute to the long-term complications associated with In this review, we summarize the evidence that nonen-
chronic renal failure and dialysis, such as dialysis-related amy- zymatic glycation and oxidation (glycoxidation) are pro-
loidosis and accelerated atherosclerosis. The increased levels foundly disturbed in renal failure and discuss their roles
of AGEs and ALEs in uremic blood and tissue proteins suggest
in uremic complications. We present evidence, however,a broad derangement in the nonenzymatic biochemistry of both
that the accumulation of glycoxidation products, a sub-carbohydrates and lipids.
class of AGEs that requires both glycation and oxidation
for their formation [1], in renal failure is only one facet
Key words: chronic renal failure, advanced glycation end product, gly- of a much broader derangement in reactive carbonylcoxidation, dialysis-related amyloidosis, atherosclerosis, uremic tox-
chemistry. We document the accumulation in uremicicity.
plasma of reactive carbonyl compounds derived from
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HISTORY OF AGE RESEARCH IN UREMIA AGE levels are thus determined by renal function and
might help in understanding the origin of uremic toxicity.The nonenzymatic reaction of carbohydrates with pro-
teins and nucleotides has been for several decades a topic
of great interest in food and nutrition biochemistry. The ORIGIN AND NATURE OF AGES IN UREMIA
so-called Maillard reaction is initiated by the attachment The origin of AGEs in diabetes is still disputed. The
of carbohydrates to protein amino groups and proceeds fact that tissue levels of AGEs correlate with prevailing
from reversible Schiff base adducts to more stable, slowly serum concentrations of glucose, fructoselysine, and gly-
reversible Amadori rearrangement products. The AGEs cated hemoglobin [5] points to a role for hyperglycemia,
eventually form irreversibly over time from the latter yet there is good evidence that other carbohydrates such
compounds, leading to covalent cross-linking of amino as ascorbate, pentoses, and metabolic intermediates may
groups of proteins. act as potent glycating agents [18–21].
Research on the role of AGEs in human pathology In uremia [4, 22], plasma AGEs are reported to exist
focused initially on normal aging and on diabetes with predominantly in the form of low molecular weight pep-
sustained hyperglycemia. Normal aging is accompanied tides (#10 kDa) that can be removed during hemodialy-
by a progressive increase of AGEs in proteins with a sis. Their accumulation has thus been ascribed to a de-
slow turnover, such as lens crystallin [2]. This process is creased renal clearance. However, these data have been
markedly enhanced in diabetic subjects in whom AGEs obtained with ELISA and radioreceptor assays in which
are increased in plasma proteins [3] and vascular and the target epitopes are unknown [4, 10]. Results obtained
skin collagens [4, 5]. The demonstration that prevailing with more specific methods yield a different insight. The
levels of AGEs are correlated with the severity of dia- AGE pentosidine, for example, is markedly raised in
betic complications [6, 7] and even predict changes in uremic plasma and is over 90% bound to serum albumin.
kidney morphology [8] supports the clinical relevance The remaining fraction is in the free rather than peptide-
of AGE modification of proteins. The causal role of bound form [14, 23]. Hemodialysis and peritoneal dial-
hyperglycemia is confirmed by the relationship between ysis clear only the free form and do not significantly
the tissue content of AGEs and the serum level of fruc- modify total plasma pentosidine [23, 24]. CML is also
toselysine, a biomarker of prevailing plasma glucose con- raised in uremic plasma. Its presence in the nondialyz-
centration [5]. able, acid-precipitable fraction of plasma [15] also sug-
The striking rise of AGEs in proteins of nondiabetic gests covalent binding to plasma proteins. Indeed, CML
uremic patients [4] indicates, however, that factors other is over 90% bound to serum albumin [17]. As long as
than hyperglycemia also determine the rate of formation the AGE moiety recognized by the antibody used in the
of AGEs. In both diabetes and uremia, formation of ELISA assay in early studies [10] remains unknown, it
AGEs is a slow process [9] that is associated with the must be assumed that circulating AGEs are linked to
development of chronic disease. Clinical research on plasma proteins, mainly albumin, that hemodialysis and
AGEs relied initially on a bioassay using a cell line able peritoneal dialysis have little impact on their clearance,
to bind AGE-modified proteins [4] and subsequently on and that AGE accumulation in plasma proteins cannot
an enzyme-linked immunosorbent assay (ELISA) using be attributed to decreased renal clearance of protein-
an antibody raised against AGE modified proteins [10], linked CML and pentosidine.
but with unknown specificity. Currently, several AGE In vitro studies have demonstrated that pentosidine is
products have been chemically identified in tissue pro- derived exclusively from carbohydrates [18, 20]. CML,
teins, including pentosidine [11], Ne-(carboxymethylly- by contrast, originates not only from carbohydrates but
sine) (CML) [12] and imidazolones [13] (Fig. 1). Specific also from metal-catalyzed oxidation of polyunsaturated
methods have also been developed to quantitate these fatty acids in lipoproteins [25] and from hypochlorous
products, such as high-performance liquid chromatogra- acid-mediated oxidation of the hydroxy-amino acid,
phy assay for pentosidine [3, 14] or a gas chromatogra- l-serine [26]. CML may thus be formed by autoxidation
phy/mass spectometry (GC/MS) assay for CML [15]. It of lipids and amino acids as well as of carbohydrates.
has thus been demonstrated that pentosidine accumu- Plasma levels of dehydroascorbate, the oxidized form
lates in plasma and in tissue collagen of uremic as well of ascorbate, correlate with plasma pentosidine levels in
as diabetic patients [3, 14, 16] and that levels of CML hemodialysis patients, confirming in vitro studies that
are elevated in plasma proteins of uremic patients [15]. dehydroascorbate may be an important AGE precursor
Levels of pentosidine and CML in plasma proteins do not in uremia [21]. Of greater interest, CML in uremic
differ between diabetic and nondiabetic hemodialysis plasma is correlated with both the malondialdehyde ad-
patients [14, 17]. Furthermore, in uremic patients, there duct to lysine (MDA-Lys), a product of lipid peroxida-
is no correlation between serum fructosamine and AGEs tion, and pentosidine [17]. The fact that the former corre-
lation is better than the latter, taken together with thein plasma or tissue proteins [14, 17]. Tissue and plasma
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Fig. 1. Structure of carbonyl stress end products.
lack of correlation between pentosidine and MDA-Lys, Altogether, these findings indicate that uremic plasma
contains elevated levels of low molecular weight AGEstrongly suggests that CML indeed originates in vivo
from both carbohydrate- and lipid-derived precursors, precursors. These precursors are neither glucose, in
which the concentration is normal, nor ascorbic acid, inwhereas pentosidine is formed from only carbohydrate
precursors. which the concentration is either normal or lowered in
uremic plasma [21], nor 3-deoxyglucosone because itsFurthermore, in vitro studies indicate that there are
elevated levels of low molecular weight AGE precursors addition to normal plasma failed to increase pentosidine
yield [27]. Based on inhibition by aminoguanidine orin uremic plasma. Plasma samples, obtained from normal
and nondiabetic hemodialysis patients, were incubated OPB-9195 and reactivity with 2,4-dinitrophenylhydraz-
under air for several weeks [27]. Generation of pentosi- ine, these precursors are probably reactive carbonyl com-
dine was monitored during the incubation. Protein- pounds derived from carbohydrates, lipids, and amino
linked pentosidine rose much more in uremic than in acids.
control plasma. This difference was still observed for
plasma ultrafiltrates (5,000 Da cut-off) incubated with
ROLE OF OXIDATIVE STRESS INnormal human albumin. The pentosidine yield in the
ACCELERATED AGE FORMATIONultrafiltrate was also significantly higher in predialysis
The formation of glycoxidation products, such as CMLthan in postdialysis plasma samples [27]. The AGE inhib-
and pentosidine, is considered the result of a second-itors aminoguanidine [28] and OPB-9195 [29] inhibited
order chemical reaction with a rate that is dependent onthe in vitro production of pentosidine in both control
the concentration of carbohydrate precursors ([CHO],and uremic plasma [27]. Because aminoguanidine and
glycative stress) and of reactive oxygen species ([O2]*,OPB-9195 act by capturing carbonyl compounds, these
oxidative stress), as shown in Equation 1.results point to an increase in reactive carbonyl com-
pounds in plasma as precursors of AGEs on plasma Rate of formation of glycoxidation products 5
proteins. Direct evidence for a raised level of carbonyl k 3 [CHO] 3 [O2]* 3 [protein] (Eq. 1)compounds has been obtained by exposure of ultrafilt-
where k is an average rate constant for reactions ofered plasma to 2,4-dinitrophenylhydrazine. Hydrazones
carbohydrates with proteins to form glycoxidation prod-formed by interaction with carbonyl groups were de-
ucts, [CHO] is the effective concentration of a variety oftected by a spectrophotometric assay [30]. The hydra-
carbohydrate precursors, and [O2]* is the level of oxidativezone yield was several times higher in uremic subjects
compared with control subjects [27]. stress as measured by the concentration of various reac-
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tive oxygen species. By contrast, the formation of imida- amino acids or indirectly by reactive carbonyl compounds
zolone and probably pyrraline does not depend on oxida- generated by the autoxidation of carbohydrates, lipids,
tive stress, and they are thus nonglycoxidative AGEs. At or amino acids. Autoxidation of carbohydrates yields
a constant protein concentration ([protein]), the steady- reactive carbonyl compounds, precursors of glycoxida-
state level of glycoxidation products depends not only tion products, such as glyoxal [40], methylglyoxal [41],
on the protein-specific rate of formation of glycoxidation and glycolaldehyde [42], as well as dehydroascorbate
products, but also on the rate of turnover of the protein. formed on oxidation of ascorbate [19, 21] (Fig. 2). Lipid
Thus, the concentration of AGEs on proteins increases in peroxidation yields other reactive carbonyl compounds,
order from plasma proteins, to hemoglobin, to collagen, some of which are identical to those formed from carbo-
consistent with the increasing life span of these proteins hydrates [25], such as glyoxal and methylglyoxal, whereas
in the body. According to Equation 1, glycoxidation others are characteristic of lipids, such as MDA and
products may increase in tissues in response to an in- 4-hydroxynonenal (HNE) [43]. The latter reactive car-
crease in either glycative or oxidative stress, that is, an bonyl compounds produce MDA- and HNE-protein ad-
increase in either [CHO] or [O2]*. ducts, also termed lipoxidation products or advanced
In diabetic patients [5], age-adjusted increases in pen- lipoxidation end products (ALEs). Oxidation of hydroxy-
tosidine and CML in skin collagen can be explained by amino acids, l-serine, and l-threonine yields glycolalde-
the duration of the disease and the long-term severity hyde and acrolein, two carbonyl compounds highly reac-
of hyperglycemia. There is no need to invoke an increase tive with proteins, leading to formation of CML and
in oxidative stress in diabetes. Indeed, age-adjusted lev- acrolein-protein adducts [26], respectively. Polyunsatu-
els of ortho-tyrosine (o-Tyr) and methionine sulfoxide rated fatty acids are also sources of acrolein that cause
(MetSO), markers of oxidative protein damage, are not the production of acrolein-protein adduct [44].
increased in the skin collagen of diabetic patients [31]. In addition to oxidative chemistry, nonoxidative path-
In nondiabetic uremic patients, by contrast, the in- ways also contribute to the formation of reactive carbonyl
creased level of pentosidine and CML in skin collagen compounds. For example, 3-deoxyglucosone is formed
and plasma proteins may be explained by an increase in nonoxidatively by rearrangement and decomposition of
oxidative stress, rather than glycative stress [32]. Evi- Amadori compounds [45] or by anaerobic metabolic re-
dence for a uremia-associated oxidative stress includes actions leading to the formation of fructose-3-phosphate,
increased serum ratios of oxidized to total ascorbate [21], which decomposes spontaneously to 3-deoxyglucosone
of oxidized to reduced glutathione [33], and of oxidized [46]. The more reactive dicarbonyl compound methylgly-
to reduced serum albumin [34], increased serum levels oxal, formed by oxidative decomposition of polyunsatu-
of “advanced oxidation protein products” [35], and of rated fatty acids [47], is also formed during anaerobic
protein carbonyls [36], as well as decreased serum activ- glycolysis by spontaneous decomposition of triose phos-
ity of glutathione-dependent enzymes [37]. Furthermore, phates and during anaerobic metabolism of acetone and
levels of the lipid peroxidation marker, MDA-Lys, are amino acids [48]. Both 3-deoxyglucosone and methylgly-
raised [17, 38]. There are significant correlations between oxal react with protein amino groups and form AGEs
serum levels of pentosidine and oxidative markers, such on proteins. The increase in 3-deoxyglucosone and its
as advanced oxidation protein products [35] and dehy- protein adducts in uremic serum [49] is evidence of the
droascorbate [21], and between levels of CML and MDA- contribution of nonoxidative chemistry to the formation
Lys in plasma proteins [17]. Roselaar et al have also of reactive carbonyl compounds and AGEs in uremia.
reported the accumulation in uremic plasma of dialyz- Although the levels of glyoxal and methylglyoxal have
able oxidants measured by electron spin resonance spec- not been measured in uremic plasma, levels of the imida-
troscopy [39]. Altogether, these findings are consistent zolium cross-links, glyoxal-lysine dimer, and methylgly-
with a generalized increase in oxidative stress. Measure-
oxal-lysine dimer are raised in plasma proteins of uremic
ment of o-Tyr and MetSO in tissue proteins from uremic
patients [50]. The raised levels of these compounds to-patients should provide additional evidence. Increased
gether with that of MDA-Lys and pentosidine suggestoxidative stress may play an important role in the genesis
a generalized increase in circulating carbonyl compoundsof AGE precursors and other reactive carbonyl com-
formed by both oxidative and nonoxidative chemistry inpounds in uremic plasma. However, as discussed in the
uremic plasma. Thus, the metabolic and chemical imbal-following section, this is not necessarily the whole story.
ances characteristic of uremia reflect not only an appar-
ent increase in oxidative stress, but a more general rise
IS THE INCREASE IN AGE-PROTEINS IN in carbonyl stress. We therefore propose that the various
UREMIA THE RESULT OF OXIDATIVE protein adducts formed by glycoxidation or lipoxidation
STRESS OR CARBONYL STRESS? reactions, such as glycoxidation and lipoxidation prod-
ucts or advanced glycation or lipoxidation end products,Proteins may be modified either directly by reactive
oxygen species with the eventual formation of oxidized should be collectively termed “carbonyl stress end prod-
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Fig. 2. Structure of reactive carbonyl com-
pounds derived from carbohydrates, ascor-
bate, lipids, and amino acids. Carbonyl stress
end products, glycoxidation, or lipoxidation
products, or advanced glycation or lipoxida-
tion end products, are formed from these car-
bonyl compounds.
ucts.” Figures 1 and 2 show the chemical structures of ing the plasma level of reactive carbonyl compounds is
not their rate of formation by either oxidative (k4) orcarbonyl stress end products and their reactive carbonyl
precursors, respectively. nonoxidative (k5 and k6) routes, but rather their rate of
excretion or detoxification (k7).The raised carbonyl stress observed in uremia is the
consequence of either an increased production or a de- In addition to renal removal, a number of enzymes
and enzymatic pathways contribute to the detoxificationcreased renal detoxification or clearance of reactive car-
bonyl compounds. The latter hypothesis is more likely, of reactive carbonyl compounds (k7), including aldose
reductases, aldehyde dehydrogenases, and the glyoxalasebecause carbonyl compounds, derived from both oxida-
tive and nonoxidative chemistry of both carbohydrates pathway. A decreased efficiency of these pathways can
readily explain the simultaneous increase of a wide rangeand lipids, have a rather low molecular weight and rise
simultaneously in uremic plasma without concomitant of reactive carbonyl compounds in uremic plasma, what-
ever their source. Interestingly, these pathways involve,changes in glycemia or lipemia. We have summarized
this hypothesis in Figure 3, which illustrates the various or intersect, the metabolism of redox coenzymes, nicotin-
amide adenine dinucleotide phosphate [NADP(H)] andfactors involved in the chemical modification of proteins
in uremia. The steady-state concentration of reactive NAD(H), and glutathione (GSH), and therefore with
the activity of antioxidant systems. Imbalances in intra-carbonyl compounds is the major variable controlling
the formation and the resultant steady-state levels of cellular redox systems, such as those reported during
pseudohypoxia in diabetes [51], may impair detoxifica-carbonyl stress end products. The major factor determin-
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Fig. 3. Routes to the formation and detoxification of reactive carbonyl compounds and carbonyl stress end products. The level of oxidative stress
is depicted as the balance between the overall rate of formation of reactive oxygen species (k1 3 [O2]) and the rate of their inactivation by
antioxidant defenses (k2 3 [O2]*). Reactive oxygen may react directly with protein (k3 3 [O2]* 3 [protein]) to form oxidized proteins containing
protein carbonyls, amino acid hydroperoxides, ortho-tyrosine, methionine sulfoxide, and other oxidative modifications of amino acids. Reactive
oxygen also reacts with reducing carbohydrates, polyunsaturated fatty acids, or amino acid substrates (k4 3 [O2]* 3 [substrate]) to yield reactive
carbonyl compounds. Reactive carbonyl compounds are also formed by nonenzymatic reactions (k5:, for example, 3-deoxyglucosone) and by
anaerobic metabolism (k6:, for example, methylglyoxal). Reactive carbonyl compounds may then be detoxified (k7 3 [reactive carbonyl compounds])
by a variety of metabolic pathways, including dehydrogenases, reductases, and the glyoxalase pathway. Otherwise, reactive carbonyl compounds
will react secondarily with protein (k8 3 [reactive carbonyl compounds] 3 [protein]) to form proteins modified by carbonyl stress end products.
The steady-state concentration of oxidized proteins and carbonyl stress end product-modified proteins depend on the balance between their rates
of formation (k3 and k8) and degradation (k9 and k10) in tissues. The increase in reactive carbonyl compounds and carbonyl stress end product-
modified proteins in diabetes may be attributed to the increase in glycemia ([Substrate]) at constant [O2]* or to increased rates of non-oxidative
formation of reactive carbonyl compounds (k5 1 k6). The increase in reactive carbonyl compounds in uremia and the resultant increase in carbonyl
stress end product-modified proteins are thought to result from an increase in their production (k4 1 k5 1 k6) and/or a decrease in their detoxification
(k7).
tion mechanisms, resulting in higher steady-state levels nohistochemistry is currently the main tool available to
investigate tissue levels of carbonyl stress end products.of reactive carbonyl compounds. Alterations of GSH
homeostasis may impair the detoxification of reactive
carbonyls via the glyoxalase pathway [48] and cause sec-
EVIDENCE FOR CARBONYL STRESSondary alterations of the dehydroascorbate:ascorbate ra-
IN UREMIAtio. Several consequences of decreased detoxification
Dialysis-related amyloidosismay mimic the appearance of oxidative stress. Raised
levels of dehydroascorbate (or methylglyoxal) in uremic The bone and joint destruction associated with chronic
plasma would suggest an increase in oxidative stress but renal failure, known as dialysis-related amyloidosis or
may be equally well accounted for by decreased levels b2-microglobulin amyloidosis, appears related to car-
bonyl stress [52, 53]. It develops in two stages. The pre-of GSH and an interaction between ascorbate and GSH
metabolism. There is thus no a priori reason to conclude clinical stage is characterized by histologic evidence of
b2-microglobulin deposits in the joints several years be-that alterations in ascorbate homeostasis in uremia are
necessarily indicative of oxidative stress. Depending on fore the onset of clinical or radiological signs. Amyloid
deposits, already present in 20% of patients within twothreshold effects and the Km of various enzymes for
GSH, changes in capacity for reactive carbonyl com- years after the start of dialysis [54], are not surrounded
by macrophages or evidence of bone destruction. Thepound detoxification may develop without affecting sig-
nificantly the antioxidant activity of GSH or ascorbate. clinical stage emerges subsequently and is characterized
by arthralgias, carpal tunnel syndrome, and radiologi-Alterations of GSH homeostasis may thus increase reac-
tive carbonyl compound levels as a result of both de- cally visible bone cysts. At this stage, the amyloid depos-
its are surrounded by macrophages [55, 56], and bonecreased detoxification activity (k7) and decreased antioxi-
dant defenses (increased [O2]*). However, the increase resorption is observed in adjacent regions.
The cause of b2-microglobulin amyloid fibril deposi-in 3-deoxyglucosone (and possibly methylglyoxal) con-
centrations in uremic plasma does not require compro- tion is not fully elucidated. The role of elevated plasma
b2-microglobulin levels is disputed, as no difference hasmised antioxidant defenses.
Of course, most of the evidence discussed up to now been found between dialysis patients with and those
without clinical evidence of complications [57]. Effortsrelates mainly to plasma levels of various carbonyl stress
end products or precursors; their relevance to intracellu- have therefore been directed toward the identification
of chemical modifications of b2-microglobulin [58, 59].lar events remains to be thoroughly documented. Immu-
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Although these studies are not complete, immunohisto- toward monocytes/macrophages [83]. Neither truncated
b2-microglobulin [58] nor deamidated b2-microglobulinchemical and chemical analyses indicate that b2-micro-
globulin amyloid deposits are modified by a range of [59] nor b2-microglobulin modified with Amadori ad-
ducts shares this capacity.carbonyl stress end products. b2-Microglobulin amyloid
plaques react not only with anti-AGE and antireceptor The biological activities of carbonyl stress–modified
proteins may account, at least in part, for bone and jointfor AGE antibodies [60–63], but also with antibodies
specific for the glycoxidation products, pentosidine and destruction in b2-microglobulin amyloidosis, transform-
ing clinically silent, early deposits into clinically manifestCML; for the lipoxidation products, MDA and HNE (T.
Miyata et al, manuscript submitted) [21, 61, 64], and for arthritis. Uremic arthropathy may thus be considered
the combined result of carbonyl stress modification ofthe nonoxidative AGE, imidazolone [65]. b2-Microglob-
ulin isolated from plasma and urine of uremic patients amyloid deposits, followed by a secondary, localized in-
flammatory response with associated oxidative stress andalso reacts with these antibodies [60, 66].
damage. In the vascular wall, the production of reactive
Atherosclerosis carbonyl compounds during the inflammatory response
may be exacerbated by a high local concentration ofLevels of carbonyl stress end products in arterial tis-
sues are higher in dialysis patients than in normal sub- polyunsaturated fatty acid–rich lipids and lipoproteins
in arteriosclerotic plaque. The resultant cross-linking ofjects [4]. Immunohistochemical examination reveals the
presence of CML, pentosidine, MDA-Lys, and HNE- plaque lipoproteins may mediate the accumulation of
lipoproteins in foam cells.protein adduct in the thickened neointima (T. Miyata et
al, manuscript submitted). The antibodies used in these Carbonyl stress may not only induce local inflamma-
tory responses, but may also initiate biological responsesstudies are highly specific as demonstrated by minimal
cross-reactivity, assessed by competition with albumin in parenchymal cells. The interaction of AGEs with their
receptors produces intracellular oxidative stress and en-modified with related epitopes [67]. The staining pat-
hances the expression of cytokines in endothelial andtern for carbonyl stress end products also corresponded
smooth muscle cells [84]. Carbonyl compounds and re-with that for protein carbonyls (See Note added in proof,
sidual carbonyl groups on AGE-modified proteins alsoNo. 1), a biomarker of oxidative protein damage [68,
react covalently with matrix or cell surface proteins and69], detected immunohistochemically following in situ
alter their structures and functions or stimulate cellulartreatment with 2,4-dinitrophenylhydrazine [70]. Colocal-
responses [85] perhaps by cross-linking to cell surfaceization of carbonyl stress end products and protein car-
proteins [86]. Exposure of murine thymocytes to reactivebonyls in the vascular tissue of uremic patients indicates
carbonyl compounds, such as MDA, glyoxal, or HNE,a wide range of chemical modifications in vascular matrix
results in phosphorylation of the tyrosine residues of aproteins.
number of intracellular proteins. This protein-tyrosine
phosphorylation is completely inhibited by pretreatment
PATHOLOGICAL ROLE OF with OPB-9195 (See Note added in proof, No. 2). These
CARBONYL STRESS data indicate that the interaction of reactive carbonyl
The presence of carbonyl stress end products on b2- compounds, either free or protein bound, with cell sur-
microglobulin in amyloid plaque and on lipoproteins in face membrane proteins can induce intracellular re-
vascular lesions may play a role in the pathogenesis of sponses, including an oxidative stress response and pro-
joint and vascular complications in uremia. Indeed, car- tein-tyrosine phosphorylation.
bonyl stress end product (AGE and/or ALE)-modified Interestingly, these various biological effects have been
proteins recruit macrophages via scavenger [71] or AGE readily demonstrated for in vitro prepared carbonyl stress
[72, 73] receptors. Proteins modified by incubation in high (AGE)–modified proteins. In contrast, CML or pentosi-
glucose medium, that is, AGE (carbonyl stress)-modified dine-modified proteins do not bind to the AGE receptor
proteins, also initiate a range of inflammatory responses, of macrophage and are unable to induce monocyte che-
including stimulation of monocyte chemotaxis [74–76], motaxis or to stimulate macrophage secretion of cytokines
secretion of inflammatory cytokines from macrophages (T. Miyata et al, unpublished observation) [83]. Other
[75, 77, 78], stimulation of collagenase secretion from carbonyl stress (AGE) structures such as 2-(2-furoyl)-
synovial cells [75], stimulation of osteoclast-induced bone 4(5)-(2-furanyl)-1H-imidazole [87], pyrraline [88], and
resorption [79, 80], proliferation of vascular smooth muscle their protein conjugates are also inactive as ligands for
cells [81], and quenching of nitric oxide activity and its the AGE receptor of peritoneal macrophage [89].
attendant smooth muscle relaxation [82]. Among the vari- Thus, other unidentified structures must be responsi-
ous forms of modified b2-microglobulin reported so far ble for the biological activities of carbonyl stress (AGE)-
in amyloid plaque, only carbonyl stress (AGE)-modified modified proteins in vitro. They may include not only
uncharacterized carbonyl stress end products but alsob2-microglobulin is endowed with a biological activity
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reactive carbonyl compounds generated during the in Carbonyl stress quenching
vitro preparation of carbonyl stress (AGE)-modified Carbonyl stress end products are formed by carbonyl
proteins such as 3,4-Dihydroxyphenylaline (DOPA; a amine chemistry between carbonyl compounds and pro-
superoxide generator), amino acid hydroperoxides, and tein amino groups. Since the discovery of aminoguanidine
chloramines [90]. There is no evidence as yet that these in 1986 [28], a number of second-generation compounds
unidentified species are also formed on proteins in vivo have been introduced that inhibit both glycoxidation and
in uremic patients or that they, if formed, reach high lipoxidation reactions. Among them, OPB-9195 (62-iso-
enough concentrations to induce a biological response. propylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide)
Still, the local concentration of carbonyl stress (AGE)- belongs to a group of thiazolidine derivatives. The hydra-
modified proteins in b2-microglobulin amyloid deposits zine nitrogen atom of OPB-9195 reacts with carbonyl
and in the thickened neointima of arteriosclerotic, ure- groups, directly or via the free base on hydrolysis to
form hydrazones (T. Miyata et al, manuscript submitted).mic arteries may be sufficient to induce pathological
This mechanism is similar to that of aminoguanidinechanges. Indeed, levels of AGEs in amyloid fibril b2-
hydrochloride. However, OPB-9195 is expected to bemicroglobulin purified from long-term hemodialysis pa-
more effective than aminoguanidine because the latter’stients are comparable to those of AGE-modified b2-
hydrazine nitrogen atom has a decreased nucleophilicitymicroglobulin prepared in vitro, which elicits biological
due to the proximity of the guanidium cation. As alreadyresponses [61].
described, OPB-9195 lowers pentosidine formation inFurthermore, we have demonstrated that the inhibi-
both uremic and control plasma upon incubation in vitro,tion of carbonyl stress end product formation prevents
and oral administration of OPB-9195 effectively inhibitscarbonyl stress–derived vascular damage in vivo. Carotid
in vivo the neointima formation of rat carotid arteryartery balloon injury in the rat induces a remarkable neo-
following balloon injury.intimal proliferation, which is an early and major event in
These compounds are thought to entrap reactive car-the formation of atherosclerotic lesions. Carbonyl stress
bonyl compounds, either free or attached to proteins.end products, for example, CML, pentosidine, MDA-
Further study is required to evaluate alternative activi-Lys, and HNE-protein adduct, are detectable immuno-
ties, such as inhibition of amine oxidases and nitric oxidehistochemically in the proliferative neointima of vascular
synthase or even antioxidant activity. The developmentwalls (T. Miyata, manuscript submitted). Oral adminis-
of less toxic and more specific carbonyl stress inhibitors istration of the carbonyl stress inhibitor, OPB-9195 (next
also an important therapeutic avenue. Such compoundssection) effectively reduces neointima formation in this
immobilized in cartridges might enhance extraction of
model (T. Miyata et al, manuscript submitted). reactive carbonyl compounds from blood during dialysis
therapy. They could prove useful for the treatment of
other conditions in which reactive carbonyl compoundsTHERAPEUTIC INSIGHTS
and carbonyl stress end products are implicated, suchThe carbonyl stress hypothesis suggests a range of
as diabetes, atherosclerosis, neurodegenerative diseases,therapeutic approaches to retarding or preventing the
and even chronic age-dependent chemical modificationscomplications associated with end-stage renal failure,
of tissue proteins.such as antioxidant supplementation, anti-inflammatory
drugs, and the use of inhibitors of reactive carbonyl NOTES ADDED IN PROOF
chemistry.
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boxymethyllysine); ELISA, enzyme-linked immunosorbent assay; GSH,stress end products.
Miyata et al: Carbonyl stress in uremia 397
glutathione; HNE, hydroxynonenal; MDA, malondialdehyde; MetSO, 18. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW: Formation of
pentosidine during nonenzymatic browning of protein by glucose:methionine sulfoxide; OPB-9195, 62-isopropylidenehydrazono-4-oxo-
thiazolidin-5-ylacetanilide. Identification of glucose and other carbohydrates as possible pre-
cursors of pentosidine in vivo. J Biol Chem 266:11654–11660, 1991
Reprint requests to: Toshio Miyata, M.D., Ph.D., Molecular and 19. Dunn JA, Ahmed MU, Murtiashaw MH, Richardson JM,
Walla MD, Baynes JW: Reaction of ascorbate with lysine andCellular Nephrology, Institute of Medical Sciences and Department of
Internal Medicine, Tokai University School of Medicine, Bohseidai, protein under autoxidizing conditions: Formation of Ne-(carboxy-
methyl) lysine by reaction between lysine and products of autoxida-Isehara, Kanagawa 259–11, Japan.
E-mail: t-miyata@is.icc.u-tokai.ac.jp tion of ascorbate. Biochemistry 29:10964–10970, 1990
20. Grandhee SK, Monnier VM: Mechanism of formation of the
Maillard protein cross-link pentosidine. J Biol Chem 266:11649–
REFERENCES 11653, 1991
21. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda1. Baynes JW: Perspectives in diabetes: Role of oxidative stress in
K, Kurokawa K, van Ypersele de Strihou C: Implication of andevelopment of complications in diabetes. Diabetes 40:405–412,
increased oxidative stress in the formation of advanced glycation1991
end products in patients with end-stage renal failure. Kidney Int2. Araki N, Ueno N, Chakrabarti B, Morino Y, Horiuchi S: Immu-
51:1170–1181, 1997nohistochemical evidence for the presence of advanced glycation
22. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM,end products in human lens proteins and its positive correlation
Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR,with aging. J Biol Chem 267:10211–10214, 1992
Cerami A, Vlassara H: Reactive glycosylation end products in3. Odetti P, Forgarty J, Sell DR, Monnier VM: Chromatographic
diabetic uraemia and treatment of renal failure. Lancet 343:1519–quantitation of plasma and erythrocyte pentosidine in diabetic and
1522, 1994uremic subjects. Diabetes 41:153–159, 1992
23. Friedlander MA, Wu YC, Elgawish A, Monnier VM: Early4. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney
and advanced glycosylation end products. J Clin Invest 97:728–735,V, Friedman EA: Advanced glycosylation end products in patients
1996with diabetic nephropathy. N Engl J Med 325:836–842, 1991
24. Miyata T, Ueda Y, Yoshida A, Sugiyama S, Iida Y, Jadoul M,5. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance
Maeda K, Kurokawa K, van Ypersele de Strihou C: ClearanceDR, Baynes JW: Accumulation of Maillard reaction products in
of pentosidine, an advanced glycation end product, by differentskin collagen in diabetes and aging. J Clin Invest 91:2463–2469,
modalities of renal replacement therapy. Kidney Int 51:880–887,1993
19976. Sell DR, Lapolla A, Odetti P, Forgarty J, Monnier VM: Pentos-
25. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpeidine formation in skin correlates with severity of complication in
SR: The advanced glycation end product, Ne-(carboxymethyl) ly-individuals with long standing IDDM. Diabetes 41:1286–1292, 1992
sine, is a product of lipid peroxidation and glycoxidation reactions.7. McCance DR, Dyer DG, Dunn JA, Dunn JA, Bailie KE, Thorpe
J Biol Chem 271:9982–9986, 1996SR, Baynes JW, Lyons TJ: Maillard reaction products and their
26. Anderson MM, Hazen SL, Hsu FF, Heinecke JW: Human neutro-relation to complications in insulin-dependent diabetes mellitus.
phils employ the myeloperoxidase-hydrogen peroxide-chlorideJ Clin Invest 91:2470–2478, 1993
system to convert hydroxy-amino acids into glycolaldehyde,8. Berg TJ, Bangstand H-J, Torjesen PA, Osterby R, Bucala R,
2-hydroxypropanol, and acrolein: A mechanism for the generationHanssen KF: Advanced glycation end products (AGEs) in serum
of highly reactive a-hydroxy and a, b-unsaturated aldehydes bypredict changes in the kidney morphology of IDDM patients. Me-
phagocytes at sites of inflammation. J Clin Invest 99:424–432, 1997tabolism 46:661–665, 1997
27. Miyata T, Ueda Y, Yasuda Y, Izuhara Y, Saito A, Jadoul9. Westwood ME, Thornalley PJ: Glycation and advanced glyca-
M, Kurokawa K, van Ypersele de Strihou C: Accumulation oftion end products, in The Glycation Hypothesis of Atherosclerosis,
carbonyls accelerates the formation of pentosidine, an advancededited by Colaco C, London, Landes Biosciences, 1997, pp 576–587
glycation end product: Carbonyl stress in uremia. J Am Soc10. Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical
Nephrol 9:2349–2356, 1998detection of advanced glycosylation end products in vivo. J Biol
28. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A:Chem 267:5133–5138, 1992
Aminoguanidine prevents diabetes-induced arterial wall protein11. Sell DR, Monnier VM: Structure elucidation of a senescence
cross-linking. Science 232:1629–1632, 1986cross-link from human extracellular matrix. J Biol Chem 264:21597–
29. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W,21602, 1989
Yanagisawa K, Kawata T, Koike T: Progression of nephropathy12. Ahmed MU, Thorpe SR, Baynes JW: Identification of Ne-carboxy-
in spontaneous diabetic rats is prevented by OPB-9195, a novelmethyllysine as a degradation product of fructoselysine in glycated
inhibitor of advanced glycation. Diabetes 46:895–899, 1997protein. J Biol Chem 261:4889–4894, 1986
30. Lynch CL, Lim CK, Thomas M, Peters TJ: Assay of blood and13. Uchida K, Khor OT, Oya T, Osawa T, Yasauda Y, Miyata T:
tissue aldehydes by HPLC analysis of their 2,4-dinitrophenylhy-Protein modification by a Maillard reaction intermediate meth-
drazine adducts. Clin Chim Acta 130:117–122, 1983ylglyoxal immunochemical detection of fluorescent 5-methylimid-
31. Wells-Knecht MC, Lyons TJ, McCance DR, Thorpe SR, Baynesazolone derivatives in vivo. FEBS Lett 410:313–318, 1997
JW: Age-dependent increase in ortho-Tyrosine and methionine14. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K,
sulfoxide in human skin collagen is not accelerated in diabetes:van Ypersele de Strihou C, Maeda K: Accumulation of albumin-
Evidence against a generalized increase in oxidative stress in diabe-linked and free-form pentosidine in the circulation of uremic pa-
tes. J Clin Invest 100:839–846, 1997tients with end-stage renal failure: Renal implications in the patho-
32. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C:physiology of pentosidine. J Am Soc Nephrol 7:1198–1206, 1996
Oxidation conspires with glycation to generate noxious advanced15. Degenhardt TP, Grass L, Reddy S, Thorpe SR, Diamandis EP,
glycation end products in renal failure. Nephrol Dial TransplantBaynes JW: The serum concentration of the advanced glycation
12:255–258, 1997end-product Ne-(carboxymethyl) lysine is increased in uremia. Kid-
33. Canestrari F, Galli F, Giorgini A, Albertini MC, Galiotta P,ney Int 52:1064–1067, 1997
Pascucci M, Bossu M: Erythrocyte redox state in uremic anemia:16. Sell DR, Monnier VM: End-stage renal disease and diabetes
Effects of hemodialysis and relevance of glutathione metabolism.catalyze the formation of a pentose-derived crosslink from aging
Acta Haematol 91:187–193, 1994human collagen. J Clin Invest 85:380–384, 1990
34. Kumano K, Yokota S, Go M, Suyama K, Sakai T, Era S, Sogami M:17. Miyata T, Fu MX, Kurokawa K, van Ypersele de Strihou C,
Quantitative and qualitative changes of serum albumin in CAPDThorpe SR, Baynes JW: Products of autoxidation of both carbohy-
patients. Adv Perit Dial 8:127–130, 1992drates and lipids are increased in uremic plasma: Evidence for
35. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Ngu-a generalized increase in oxidative stress in uremia? Kidney Int
54:1290–1295, 1998 yen-Khoa T, Nguyen AN, Zingraff J, Jungers P, Descamps-
Miyata et al: Carbonyl stress in uremia398
Latscha B: Advanced oxidation protein products as a novel marker 56. Argiles A, Mourad G, Kerr PG, Garcia M, Collins B, Demaille
of oxidative stress in uremia. Kidney Int 49:1304–1313, 1996 JG: Cells surrounding haemodialysis-associated amyloid deposits
36. Odetti P, Garibaldi S, Gurreri G, Aragno I, Dapino D, Pron- are mainly macrophages. Nephrol Dial Transplant 9:662–667, 1994
zato MA: Protein oxidation in hemodialysis and kidney trans- 57. Gejyo F, Homma N, Suzuki Y, Arakawa M: Serum levels of
plantation. Metabolism 45:1319–1322, 1996 b2-microglobulin as a new form of amyloid protein in patients
37. Yeung JH: Effects of glycerol-induced acute renal failure on tissue undergoing long-term hemodialysis. N Engl J Med 314:585–586,
glutathione and glutathione-dependent enzymes in the rat. Meth- 1986
ods Find Exp Clin Pharmacol 13:23–28, 1991 58. Linke RP, Hampl H, Lobeck H, Ritz E, Bommer J, Waldherr R,
38. Dasgupta A, Hussain S, Ahmad S: Increased lipid peroxidation Eulitz M: Lysine-specific cleavage of b2-microglobulin in amyloid
in patients on maintenance hemodialysis. Nephron 60:56–59, 1992 deposits associated with hemodialysis. Kidney Int 36:675–681, 1989
39. Roselaar SE, Nazhat NB, Winyard PG, Jones P, Cunningham 59. Odani H, Oyama R, Titani K, Ogawa H, Saito A: Purification
J, Blake DR: Detection of oxidant in uremic plasma by electron and complete amino acid sequence of novel b2-microglobulin.
spin resonance spectroscopy. Kidney Int 48:199–206, 1995 Biochem Biophys Res Commun 168:1223–1229, 1990
40. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, 60. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchi
Baynes JW: Mechanism of autoxidative glycosylation: Identifica- S, Taniguchi N, Maeda K, Kinoshita T: b2-Microglobulin modi-
tion of glyoxal and arabinose as intermediates in the autoxidative fied with advanced glycation end products is a major component of
modification of protein by glucose. Biochemistry 34:3702–3709, hemodialysis-associated amyloidosis. J Clin Invest 92:1243–1252,
1995 1993
41. Ahmed MA, Frye EB, Thorpe SR, Baynes JW: Ne-(carboxy- 61. Miyata T, Taneda S, Kawai R, Ueda Y, Horiuchi S, Hara M,
methyl) lysine, a product of the chemical modification of proteins Maeda K, Monnier VM: Identification of pentosidine as a native
by methylglyoxal, increases with age in human lens proteins. Bio- structure for advanced glycation end products in b2-microglobulin-
chem J 324:565–570, 1997 containing amyloid fibrils in patients with dialysis-related amy-
42. Glomb MA, Monnier VM: Mechanism of protein modification by loidosis. Proc Natl Acad Sci USA 93:2353–2358, 1996
glyoxal and glycolaldehyde, reactive intermediates of the Maillard 62. Niwa T, Miyazaki S, Katsuzaki T, Tatemichi N, Takei Y, Miya-
reaction. J Biol Chem 276:10017–10025, 1995 zaki T, Morita T, Hirasawa Y: Immunohistochemical detection
43. Esterbauer H, Schuer RJ, Zollner H: Chemistry and biochemis- of advanced glycation end products in dialysis-related amyloidosis.
try of 4-hydroxynonenal, malondialdehyde and related aldehyde. Kidney Int 48:771–778, 1995
Free Radic Biol Med 11:81–128, 1991 63. Miyata T, Hori O, Zhang JH, Yan SD, Ferran L, Iida Y, Schmidt
44. Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Su- AM: The receptor for advanced glycation end products mediates
zuki D, Miyata T, Noguchi N, Niki E, Osawa T: Protein-bound the interaction of AGE-b2-microglobulin with human mononu-
acrolein: Potential markers for oxidative stress. Proc Natl Acad clear phagocytes via an oxidant-sensitive pathway: Implication for
Sci USA 95:4882–4887, 1998 the pathogenesis of dialysis-related amyloidosis. J Clin Invest
45. Lal S, Szwergold BS, Taylor AH, Randall WC, Kappler F, 98:1088–1094, 1997
Wells-Knecht KJ, Baynes JW, Brown TR: Metabolism of fruc- 64. Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichitose-3-phosphate in the diabetic rat lens. Arch Biochem Biophys N, Takei Y, Kondo T: Amyloid b2-microglobulin is modified with318:191–199, 1995
Ne-(carboxymethyl) lysine in dialysis-related amyloidosis. Kidney46. Hayashi T, Namiki M: Role of sugar fragmentation in the Maillard
Int 50:1303–1309, 1996reaction, in Amino-Carbonyl Reaction in Food and Biological Sys-
65. Niwa T, Katsuzaki T, Miyazaki S, Momoi T, Akiba T, Miyazakitems, edited by Fujimaki M, Namiki M, Kato H, Amsterdam,
T, Nokura K, Hayase F, Tatemichi N, Takei Y: Amyloid b2-Elsevier, 1986, pp 29–38
microglobulin is modified with imidazolone, a novel advanced gly-47. Mlakar A, Spiteller G: Reinvestigation of lipid peroxidation of
cation end product, in dialysis-related amyloidosis. Kidney Intlinolenic acid. Biochim Biophys Acta 1214:209–220, 1994
51:187–194, 199748. Thornalley PJ: Advanced glycation and development of diabetic
66. Miyata T, Inagi R, Wada Y, Ueda Y, Iida Y, Takahashi M,complications: Unifying the involvement of glucose, methylglyoxal
Taniguchi N, Maeda K: Glycation of human b2-microglobulin inand oxidative stress. Endocrinol Metab 3:149–166, 1996
patients with hemodialysis-associated amyloidosis: Identification49. Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Saito
of the glycated sites. Biochemistry 33:12215–12221, 1994A, Miyazaki S, Maeda K, Tatemichi N, Takei Y: Modification of
67. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, vanb2m with advanced glycation end products as observed in dialysis-
Ypersele de Strihou C, Monnier VM, Witztum JL, Kurokawa K:related amyloidosis by 3-DG accumulating in uremic serum. Kid-
Immunohistochemical colocalization of glycoxidation products andney Int 49:861–867, 1996
lipid peroxidation products in diabetic renal glomerular lesions. J50. Odani H. Shinzato T, Usami J, Matsumoto Y, Brinkmann Frye
Clin Invest 100:2995–3004, 1997E, Baynes HW, Maeda K: Imadazolium crosslinks derived from
68. Stadtman ER, Oliver CN: Metal catalyzed oxidation of proteins:reaction of lysine with glyoxal and methylglyoxal are increased in
Physiological consequences. J Biol Chem 266:2005–2008, 1991serum proteins of uremic patients: Evidence for increased oxidative
69. Stadtman ER: Protein oxidation and aging. Science 257:1220–1224,stress in uremia. FEBS Lett 427:381–385, 1998
199251. Williamson JR, Chang K, Khalid MF, Hasan KS, Ido Y, Kawa-
70. Smith MA, Perry G, Richey PL, Anderson VE, Beal MF,mura T, Nyengaard JR, van den Enden M, Kilo C, Tilton
Kowall N: Oxidative damage in Alzheimer’s. Nature 382:120–121,RG: Hyperglycemic pseudohypoxia and diabetic complications.
1996Diabetes 42:801–813, 1993
71. Kodama T, Freeman M, Rohrer L, Zabrechy J, Matsudaira P,52. Miyata T, Maeda K: Pathogenesis of dialysis-related amyloidosis.
Kreiger M: Type I macrophage scavenger receptor contains alpha-Curr Opin Nephrol Hypertens 4:493–497, 1995
helical and collagen-like coiled coil. Nature 343:531–535, 199053. Miyata T, Jadoul M, Kurokawa K, van Ypersele de Strihou C:
72. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC,b2-Microglobulin in renal disease. J Am Soc Nephrol 9:1723–1735,
Elliston K, Stern D, Shaw A: Cloning and expression of a cell1998
surface receptor for advanced glycosylation end products of pro-54. Jadoul M, Garbar C, Noel H, Sennesael J, Vanholder R, Ber-
teins. J Biol Chem 267:14998–15004, 1992naert P, Rorive G, Hanique G, van Ypersele de Strihou C:
73. Schmidt AM, Yon SD, Brett J, Mora R, Nowygrod R, SternHistological prevalence of b2-microglobulin amyloidosis in haemo-
D: Regulation of human mononuclear phagocyte migration by celldialysis: A prospective post-mortem study. Kidney Int 51:1928–
surface-binding proteins for advanced glycation end products. J1932, 1997
Clin Invest 92:2155–2168, 199355. Ohashi K, Hara M, Kawai R, Ogura Y, Honda K, Nihei H,
74. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H:Mimura N: Cervical discs are most susceptible to beta2-microglob-
Advanced protein glycosylation induces transendothelial humanulin amyloid deposition in the vertebral column. Kidney Int
41:1646–1652, 1992 monocyte chemotaxis and secretion of platelet-derived growth fac-
Miyata et al: Carbonyl stress in uremia 399
tor: Role in vascular disease of diabetes and aging. Proc Natl Acad ucts quench nitric oxide and mediate defective endothelium-depen-
dent vasodilatation in experimental diabetes. J Clin Invest 87:432–Sci USA 87:9010–9014, 1990
75. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda M, 438, 1991
83. Miyata T, Iida Y, Ueda Y, Shinzato T, Seo H, Monnier VM,Seo H: Involvement of b2-microglobulin modified with advanced
glycation end products in the pathogenesis of hemodialysis-associ- Maeda K, Wada Y: Monocyte/macrophage response to b2-micro-
globulin modified with the advanced glycation end products. Kid-ated amyloidosis: Induction of human monocyte chemotaxis and
macrophage secretion of tumor necrosis factor-a and interleukin-1. ney Int 49:538–550, 1996
84. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, ZouJ Clin Invest 93:521–528, 1994
76. Cai T, Miyata T, Horie K, Iida Y, Maeda K: b2-Microglobulin YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the
interaction of advanced glycation end products with their recep-modified with advanced glycation end products induces monocyte
chemotaxis in vivo. Nephrol Dial Transplant 11:1189–1191, 1996 tors/binding proteins. J Biol Chem 269:9889–9897, 1994
85. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola77. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasa-
gian A: Cachectin/TNF and IL-1 induced by glucose-modified S, Vogl S, Poli G: The lipoxidation end product 4-hydroxy-2,3-
nonenal upregulates transforming growth factor b1 expression inproteins: Role in normal tissue remodeling. Science 240:1546–1548,
1988 macrophage lineage: A link between oxidative injury and fibro-
sclerosis. FASEB J 11:851–857, 199778. Iida Y, Miyata T, Inagi R, Sugiyama S, Maeda K: b2-Microglobu-
lin modified with advanced glycation end products induces interleu- 86. Rhodes J: Covalent chemical events in immune induction: Funda-
mental and therapeutic aspects. Immunol Today 9:436–441, 1996kin-6 from human macrophages: Role in the pathogenesis of hemo-
dialysis-associated amyloidosis. Biochem Biophys Res Commun 87. Pongor S, Ulrich PC, Bencsath FA, Cerami A: Aging of proteins:
Isolation and identification of a fluorescent chromophore from the201:1235–1241, 1994
79. Miyata T, Sprague SM: Advanced glycation of b2-microglobulin in reaction of polypeptides with glucose. Proc Natl Acad Sci USA
81:2684–2688, 1984the pathogenesis of bone lesions in dialysis associated amyloidosis.
Nephrol Dial Transplant 11(Suppl 3):86–90, 1996 88. Njoroge FG, Sayre LM, Monnier VM: Detection of glucose-
derived pyrrole compounds during Maillard reaction under physio-80. Miyata T, Notoya K, Yoshida K, Horie K, Kurokawa K, Maeda
K, Taketomi S: Advanced glycation end products enhance osteo- logical conditions. Carbohydr Res 167:211–220, 1987
89. Takata K, Horiuchi S, Araki N, Shiga M, Saitoh M, Morinoclast-induced bone resorption in cultured mouse unfractionated
bone cells and in rats implanted subcutaneously with devitalized Y: Endocytic uptake of nonenzymatically glycosylated proteins is
mediated by a scavenger receptor for aldehyde-modified proteins.bone particles. J Am Soc Nephrol 8:260–270, 1997
81. Satoh H, Togo M, Hara M, Miyata T, Han K, Maekawa H, J Biol Chem 263:14819–14825, 1988
90. Fu S, Fu MX, Baynes JW, Thorpe SR, Dean RT: Presence ofOhno M, Hashimoto Y, Kurokawa K, Watanabe T: Advanced
glycation end products stimulate mitogen-activated protein kinase DOPA and amino acid hydroperoxides in proteins modified with
advanced glycation end products (AGEs): Amino acid oxidationand proliferation in rabbit vascular smooth muscle cells. Biochem
Biophys Res Commun 239:111–115, 1997 products as possible source of oxidative stress induced by AGE-
proteins. Biochem J 330:233–239, 199882. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation prod-
